Welcome to our dedicated page for United States Antimony SEC filings (Ticker: UAMY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The United States Antimony Corporation (UAMY) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. UAMY’s common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and trades on the NYSE American and NYSE Texas, so investors can review a range of filings, including Form 8-K current reports that detail material events and corporate developments.
Recent Form 8-K filings for United States Antimony cover topics such as entry into material definitive agreements, including a five-year supply agreement with a U.S. industrial fabric manufacturer for antimony trioxide, and capital markets transactions under shelf registration statements and sales agreements. Other 8-Ks report on operational updates, preliminary revenue guidance, and proposals related to potential acquisitions, as well as the appointment of new independent directors and the formation of board committees.
Filings also disclose information about conference calls and press releases reporting financial and operational results for periods such as the third quarter and nine months ended September 30, 2025. These documents outline revenues, gross profit, operating expenses, net loss, and balance sheet data, along with narrative discussion of antimony and zeolite sales and capital expenditures for smelter expansion and mineral rights purchases.
On this page, Stock Titan pairs real-time updates from the SEC’s EDGAR system with AI-powered summaries that help explain the significance of each filing. Investors can quickly scan Form 8-K disclosures for key points on contracts, financing, governance changes, and operational guidance, and then dive into the full text when more detail is needed. For those tracking UAMY’s role in antimony, zeolite, and critical minerals, these filings provide an official record of the company’s regulatory and financial reporting.
United States Antimony Corporation filed a Form 8-K stating it issued a press release on October 30, 2025 with an operational update and a preliminary update to Fiscal 2026 revenue guidance. The press release is included as Exhibit 99.1.
The company furnished this information under Item 7.01 (Regulation FD Disclosure), which means it is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference unless specifically noted.
United States Antimony Corporation (UAMY) filed an 8‑K announcing a non‑binding, indicative proposal to acquire Larvotto Resources Limited. On October 17, 2025, USAC submitted terms offering six (6) USAC shares for every one hundred (100) Larvotto shares. The company also disclosed it has recently acquired approximately 10% of Larvotto’s ordinary shares.
The proposal is subject to negotiation and execution of a binding scheme implementation deed, Larvotto shareholder approval, regulatory approvals, and customary closing conditions. USAC furnished a related press release under Regulation FD. The disclosure outlines the proposed share‑for‑share ratio and approvals required, indicating an early, non‑binding stage in a potential combination.
United States Antimony Corporation filed a prospectus supplement for an at‑the‑market program to offer and sell up to $400,000,000 of common stock under its automatic shelf registration on Form S‑3. Sales may be made through A.G.P./Alliance Global Partners and B. Riley Securities pursuant to an amended and restated sales agreement.
Offerings will be made only by means of the prospectus supplement and the base prospectus. A legal opinion from Duane Morris LLP regarding the validity of the shares was filed as Exhibit 5.1.
United States Antimony Corporation commenced an at-the-market offering of up to $400,000,000 of common stock, to be sold from time to time through A.G.P./Alliance Global Partners and B. Riley Securities as agents or principals. Sales may be made pursuant to Rule 415(a)(4) with no minimum amount required.
The company will pay the Agents up to 3.0% of the gross sales price per share and plans to use any net proceeds to acquire antimony and other critical mineral inventory, expand leasehold positions in Alaska and Montana, pursue acquisitions, potentially increase capacity at the Madero Smelter in Mexico, and for general working capital.
As context, the last reported sale price was $16.71 per share on October 13, 2025, and shares outstanding were 138,878,411 as of that date. The filing illustrates potential dilution: at an assumed price of $16.71, pro forma as adjusted net tangible book value would be $3.24 per share, implying $13.47 per-share dilution to new investors.
United States Antimony Corporation entered a Securities Purchase Agreement for a registered direct offering of 2,377,657 shares of common stock at $10.50 per share, for approximately $25 million in gross proceeds. The company expects net proceeds of $24,431,090.53 after the placement commission and a credit, with closing expected on or about October 14, 2025, subject to customary conditions.
The deal is being made off the company’s effective Form S-3 shelf and a Rule 462(b) S-3MEF. Titan Partners Group acted as exclusive placement agent with a 7% commission, subject to a credit. Separately, the company reduced its ATM capacity from $65,000,000 to $39,885,000 effective October 6, 2025, and as of October 10, 2025, cannot sell under the existing ATM prospectus supplement unless and until new offering documents are filed; the sales agreement remains in force.
United States Antimony Corporation is conducting a primary offering of 2,377,657 shares of common stock at $10.50 per share, for gross proceeds of $24,965,398.50. Titan Partners Group LLC is acting as exclusive placement agent on a best-efforts basis and will receive a 7.0% cash fee, with net proceeds to the company, after fees, reimbursable expenses and a closing credit, stated as $24,431,090.53.
Shares outstanding are expected to increase to 138,878,411 from 136,500,754 as of October 9, 2025. The company plans to use the funds to buy additional antimony and other critical mineral inventories, expand leasehold positions in Alaska and Montana, pursue acquisitions of critical mineral businesses or properties, potentially increase capacity at its Madero smelter in Mexico, and for general working capital. The company highlights that new investors will face immediate dilution, with pro forma net tangible book value moving to $1.00 per share versus the $10.50 offering price.
John M. Keane, a director of United States Antimony Corp (UAMY), filed an Initial Statement of Beneficial Ownership reporting no currently owned common shares and two time‑based awards granted on 08/19/2025. The filing shows 68,200 restricted stock units (RSUs) and a stock option covering 34,100 shares, each vesting one‑third on 08/19/2026, 08/19/2027, and 08/19/2028$4.26 and an expiration date of 08/19/2035. The RSUs convert to common stock at vesting; no direct common shares were reported.
United States Antimony Corporation entered into a Securities Purchase Agreement on October 6, 2025 for a registered direct offering of 3,500,000 shares of common stock at $7.50 per share. This will provide aggregate gross proceeds of approximately $26,250,000, with expected net proceeds of $25,558,750 after placement agent fees, a credit, and other expenses.
A.G.P./Alliance Global Partners acted as exclusive placement agent and will receive a 7% commission on the Offering’s gross proceeds, subject to a credit on the closing date. The Offering is being made under the company’s effective Form S-3 shelf registration statement and is expected to close on or about October 7, 2025, subject to customary conditions.
The company also adjusted its at-the-market (“ATM”) offering program. It reduced the ATM prospectus supplement’s aggregate offering price from $65,000,000 to $39,885,000. After accounting for $9,775,549 of prior ATM sales, the company may offer up to an additional $30,109,451 of common stock under the current ATM limit, while the underlying sales agreement with the agents remains in effect.
United States Antimony Corporation is offering 3,500,000 shares of common stock at $7.50 per share, for gross proceeds of $26.25 million. The deal is a best-efforts placement through A.G.P./Alliance Global Partners to a single purchaser, with the placement agent earning a 7.0% cash fee, partially offset by a credit.
The company expects net proceeds of approximately $25.4 million (about $25.56 million after fees, expenses and the credit), which it plans to use for working capital, buying additional antimony and other critical mineral inventory, expanding leasehold positions, potential acquisitions of critical mineral assets or companies, and possible expansion of its Madero smelter in Mexico above its 200‑ton‑per‑month capacity.
Shares outstanding were 131,092,887 as of October 3 2025 and are expected to be 134,592,887 after the offering. The company highlights that new investors will face immediate dilution, as pro forma net tangible book value would rise to $0.78 per share versus the $7.50 offering price.
United States Antimony Corporation filed a Form 8-K to share that, on October 6, 2025, it issued a press release announcing the pricing of a registered direct offering. The company is using this current report to make the information broadly available under Regulation FD, which is designed to ensure that all investors receive important company information at the same time.
The press release, dated October 6, 2025, is included as an exhibit to the report and is incorporated by reference. The company also clarifies that this disclosure is being treated as “furnished” rather than “filed,” which limits how it is used for certain legal liability purposes under the securities laws.